Satellos Bioscience has shared encouraging six-month updates from their TRAILHEAD clinical trial. This study is testing an experimental daily oral treatment (a pill) called SAT-3247 in adults living with Duchenne muscular dystrophy. SAT-3247 is an investigational small molecule inhibitor of adaptor-associated protein kinase 1 (AAK1), which means it is a protein that plays a key role in regulating the body’s natural muscle repair and regeneration process. In Duchenne, normal muscle repair and regeneration are disrupted. SAT-3247 is designed to restore the biological signals needed for muscle repair.
The new data comes from four adult participants, aged 21 to 28 years, who have been taking the oral treatment for an average of 186 days. Here’s what stood out:
- Strength held steady — including handgrip strength, which had nearly doubled during an earlier 28-day study and stayed at that improved level through six months
- Muscle damage marker dropped — creatine kinase (CK), a blood marker of active muscle damage, fell by an average of 38%
- Muscle quality improved — MRI scans showed fat within arm muscles decreased by an average of 3.7% (from 49.7% to 46.0%)
- Real-world activity increased — wearable sensors tracking movement showed about a 34% increase in maximum upper-limb effort
- Fatigue improved — patient-reported fatigue scores went up
- Upper limb function held or improved — a standard function test (PUL2.0) improved in two participants and stayed stable in the other two, notable since decline is typically expected over time
- Well tolerated — no serious side effects, no one stopped treatment due to side effects, and 100% dosing compliance
This progress builds on more good news Satellos shared earlier this summer. On June 29, 2026, it was announced that the U.S. Food and Drug Administration (FDA) granted SAT-3247 Fast Track designation for Duchenne. Fast Track designation is a U.S. regulatory process intended to speed up the development and review for drugs treating serious medical conditions with unmet treatment needs. It does not impact the Canadian regulatory review pathway, but it’s a strong signal of the drug’s progress and potential. This research holds significance for the Canadian Duchenne community as Satellos Bioscience is a Canadian company based in Toronto, Ontario. Having a Canadian company leading this work keeps Canada closely connected to the science as it develops.
Importantly, SAT-3247 continues to be well tolerated. There were no serious side effects related to the drug, no one stopped treatment because of side effects, and participants took their doses as directed. This is a very small study, so these results should be seen as early and encouraging rather than definitive but they give real reason for hope.
For our Canadian Duchenne community, this news is a reminder of how closely connected we are to the future of Duchenne research. A made-in-Canada company is helping advance a treatment, and Defeat Duchenne Canada will continue following this progress closely on your behalf.
Read the full press release below for more information.
Want to know more about Duchenne Research?
Scientists and medical experts have been tirelessly pursuing diverse approaches to defeat Duchenne muscular dystrophy. From tackling the root cause to alleviating symptoms, the field of research is vast and promising. Explore the various strategies being developed and tested, and gain insights into the future of muscular dystrophy treatment: